Regulatory tracker: J&J scores EU approval for Tecvayli-Darzalex combo

Johnson & Johnson (JNJ) received European Commission approval for TECVAYLI® (teclistamab) plus daratumumab for relapsed or refractory multiple myeloma. The approval, based on Phase 3 data, allows use as early as second-line treatment. This adds to JNJ's oncology portfolio and supports its strategy to offset exclusivity losses on older drugs.

Johnson & Johnson (JNJ) received FDA 510(k) clearance for MONARCH QUEST 3, a software update for its robotically assisted bronchoscopy platform. The update enhances planning, navigation, and targeting capabilities, with AI-powered features and broader imaging compatibility. JNJ stock gained 1.9% post-announcement and 29.2% year-to-date. The company also received FDA authorization for its OTTAVA Robotic Surgical System and approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform.

Johnson & Johnson (JNJ) announced EU approval for TECVAYLI (teclistamab) combined with daratumumab to treat relapsed or refractory multiple myeloma after at least one prior therapy. The approval is based on Phase 3 data showing an 83.4% reduction in disease progression or death risk compared to standard care. JNJ's stock closed at $267.37, down 2.21%, and is up 0.03% in pre-market trading.

The European Commission approved Johnson & Johnson's TECVAYLI® (teclistamab) combined with daratumumab for treating relapsed/refractory multiple myeloma. The approval, based on Phase 3 study data, shows significant improvements in progression-free and overall survival. The combination therapy demonstrated an 83.4% reduction in disease progression or death risk compared to standard care. Johnson & Johnson highlights the potential to redefine treatment standards for this patient group.

Johnson & Johnson (JNJ) reported operational sales growth led by its Innovative Medicine and MedTech businesses, raised its full-year outlook, and secured FDA clearance for MONARCH QUEST 3 AI-enabled bronchoscopy software. The company aims for $120.5B revenue and $28.6B earnings by 2029, with 7.2% yearly revenue growth. Analysts note MedTech's potential growth but highlight risks like talc litigation and biosimilar pressure.

Johnson & Johnson received U.S. regulatory clearance for MONARCH QUEST 3, a software update for its robotically-assisted bronchoscopy platform. The update enhances planning, navigation, and targeting capabilities, leveraging AI and expanding imaging integration. The company aims to improve procedural confidence and precision for clinicians. JNJ has launched three updates in 18 months, demonstrating its commitment to innovation in this area.